View in EDS HTML Full Text PDF Full Text

Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain.

Saved in:
Bibliographic Details
Title: Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain.
Authors: Mazagatos, Clara1,2 (AUTHOR) cmazagatos@isciii.es, Mendioroz, Jacobo3 (AUTHOR), Rumayor, Mercedes Belén4 (AUTHOR), Gallardo García, Virtudes5 (AUTHOR), Álvarez Río, Virginia6 (AUTHOR), Cebollada Gracia, Ana Delia7 (AUTHOR), Batalla Rebollo, Noa8 (AUTHOR), Barranco Boada, María Isabel9 (AUTHOR), Pérez‐Martínez, Olaia10 (AUTHOR), Lameiras Azevedo, Ana Sofía11 (AUTHOR), López González‐Coviella, Nieves12 (AUTHOR), Castrillejo, Daniel13 (AUTHOR), Fernández Ibáñez, Ana14 (AUTHOR), Giménez Duran, Jaume15,16 (AUTHOR), Ramírez Córcoles, Cristina17 (AUTHOR), Ramos Marín, Violeta18 (AUTHOR), Larrauri, Amparo1,2 (AUTHOR), Monge, Susana1,19 (AUTHOR), Basile, Luca (AUTHOR), García Comas, Luis (AUTHOR)
Source: Influenza & Other Respiratory Viruses. May2024, Vol. 18 Issue 5, p1-6. 6p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:17502640
DOI:10.1111/irv.13294